
Shire chief financial officer steps down
pharmafile | February 17, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Shire, hetherington
Shire’s chief financial officer (CFO) Graham Hetherington has notified the company of his decision to step down.
Flemming Ornskov, Shire chief executive said: “After a distinguished thirty-five year corporate career, including almost six years at Shire, Graham has decided he wants to spend more time with his family and to pursue his many outside interests.”
From March its senior VP and group financial controller, James Bowling, will be appointed in the interim as the firm looks for a successor.
Bowling joined Shire in 2005 and has led Shire’s financial reporting, financial planning & analysis, and treasury & insurance teams. As part of his role, Bowling has had regular interaction with the firm’s board of directors.
Hetherington (pictured) said: “I have enjoyed my years with Shire and after 35 years in corporate life, now is the moment to start spending more time with my family.”
Ornskov said of Hetherington: “We are grateful for his many contributions to Shire and, on behalf of the company, we wish him well.” He added: “I am pleased that we will have an excellent interim leader in James Bowling. Our 2013 results and our confident 2014 outlook demonstrate that Shire is in a strong position and has a great future of growth ahead.”
Related Content

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …

Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …






